Raymond James Financial Inc. Invests $8.49 Million in Moderna, Inc. (NASDAQ:MRNA)

Raymond James Financial Inc. purchased a new position in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 204,249 shares of the company's stock, valued at approximately $8,493,000. Raymond James Financial Inc. owned about 0.05% of Moderna at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in the business. Arizona State Retirement System grew its position in shares of Moderna by 1.5% in the 4th quarter. Arizona State Retirement System now owns 94,859 shares of the company's stock valued at $3,944,000 after buying an additional 1,446 shares during the last quarter. Proficio Capital Partners LLC grew its holdings in shares of Moderna by 4,418.9% during the fourth quarter. Proficio Capital Partners LLC now owns 147,360 shares of the company's stock worth $6,127,000 after purchasing an additional 144,099 shares during the last quarter. M&T Bank Corp increased its position in shares of Moderna by 10.1% during the fourth quarter. M&T Bank Corp now owns 17,759 shares of the company's stock worth $739,000 after purchasing an additional 1,622 shares in the last quarter. Commerzbank Aktiengesellschaft FI lifted its holdings in shares of Moderna by 101.4% in the 4th quarter. Commerzbank Aktiengesellschaft FI now owns 12,261 shares of the company's stock valued at $483,000 after purchasing an additional 6,174 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. grew its stake in Moderna by 9.9% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 2,344,203 shares of the company's stock worth $97,472,000 after buying an additional 211,426 shares during the last quarter. Hedge funds and other institutional investors own 75.33% of the company's stock.

Remove Ads

Moderna Stock Performance

NASDAQ MRNA traded down $0.14 during trading hours on Tuesday, reaching $34.04. The company's stock had a trading volume of 889,855 shares, compared to its average volume of 6,643,128. The company's 50-day moving average is $34.89 and its two-hundred day moving average is $45.39. Moderna, Inc. has a fifty-two week low of $29.25 and a fifty-two week high of $170.47. The stock has a market cap of $13.16 billion, a PE ratio of -3.67 and a beta of 1.86.

Analyst Ratings Changes

Several research firms recently commented on MRNA. Royal Bank of Canada reiterated a "sector perform" rating and issued a $40.00 price target on shares of Moderna in a research report on Tuesday, February 18th. Barclays downgraded shares of Moderna from an "overweight" rating to an "equal weight" rating and cut their price objective for the stock from $111.00 to $45.00 in a research report on Tuesday, February 18th. UBS Group lowered their target price on shares of Moderna from $96.00 to $78.00 and set a "buy" rating on the stock in a report on Wednesday, February 19th. JPMorgan Chase & Co. dropped their price target on shares of Moderna from $40.00 to $33.00 and set an "underweight" rating on the stock in a research note on Friday. Finally, Berenberg Bank raised their price objective on shares of Moderna from $33.00 to $42.00 and gave the company a "hold" rating in a research report on Thursday, January 16th. Four analysts have rated the stock with a sell rating, sixteen have issued a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, Moderna has an average rating of "Hold" and a consensus target price of $59.00.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.